Retatrutide is a next-generation triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. It represents one of the most studied multi-pathway metabolic research compounds in current literature.
Compound Details:
— Compound: Retatrutide (LY3437943)
— Receptor Targets: GLP-1R, GIPR, GcgR
— Vial Content: 30mg
— Form: Lyophilized powder
Retatrutide is studied for its simultaneous activity across three distinct metabolic receptor pathways. Research has examined how triple receptor engagement compares to dual and single agonist models in terms of metabolic signaling, appetite regulation, and energy expenditure research outcomes. Its multi-receptor targeting profile makes it a unique model compound for researchers studying incretin biology and the intersection of GLP-1, GIP, and glucagon signaling within a single experimental framework. Currently among the most referenced compounds in next-generation metabolic research literature.
Supplied lyophilized in a sterile sealed vial. Third-party tested for identity and purity prior to release. Not for human consumption. For research use only.
Reviews
There are no reviews yet.